Let’s face it… we work in a crazy industry.
Nobody who has spent any significant portion of their career within it would deny that the global pharmaceutical & biopharmaceutical industry is a sometimes volatile one – with many opportunities, but also several unexpected “hazards” along the way. The market is expected to continue its growth, expansion, and evolving M&As throughout 2019, and with it will come the series of upsets and changes that make it difficult to know which decisions are best for your long-term drug project.
At KCAS we know how you feel about these decisions (and the industry in which you must make them) because we’ve been doing this for over 40 years – and we like to think that our customers have come to see KCAS as a “safe zone” in the tempest of a historically stormy marketplace. Led by strong, recognized pharmaceutical and biopharmaceutical experts and pioneers in bioanalytical and biomarker services, KCAS has proven success with over 40-years of stable, secure growth.We’ve been doing this long enough to know what it’s like when things change and how to best deal with them as they do.
So how do we make our customers feel safe? By showing them that we have learned to look ahead and forecast what is coming. By combining our decades of experience with the themes and trends we monitor throughout the bioanalytical playing field, we are constantly updating our internal forecasts and using them as a guidelight toward the future. This allows KCAS to stay months (and in some cases even years) ahead of our competition in terms of what to expect and – if necessary – how we could slightly change course in order to best stay on path and continue reaching the goals we’ve laid out for ourselves and our customers.
Using our forecasting methods, we feel we understand the industry and this allows us to plan ahead to ensure responsive start times for your project. Depending on what you need, we are often able to start immediately! And that responsiveness carries its way throughout the rest of the projects you send to KCAS – and we can do a lot of them! KCAS offers services from Discovery work to Method Development; and even Sample Analysis for Pre-Clinical and Clinical Studies. By allowing KCAS to follow your molecule throughout the testing pipeline, there is no need for additional fees incurred for Method Transfer, Validation or Feasibility.
KCAS’ history of low in-house ISR (Incurred Sample Re-analysis) helps our customers feel safe.